Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia.

International Journal of Hematologic Oncology Pub Date : 2023-02-01 DOI:10.2217/ijh-2022-0005

Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf

{"title":"Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia.","authors":"Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf","doi":"10.2217/ijh-2022-0005","DOIUrl":null,"url":null,"abstract":"Aim: The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.Methods: A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.Results: At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.Conclusion: Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/69/ijh-12-42.PMC9979159.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2022-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.

Methods: A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.

Results: At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.

Conclusion: Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.

Abstract Image

查看原文本刊更多论文

提高青少年和青壮年t细胞急性淋巴细胞白血病患者的生存率。

目的:t细胞急性淋巴细胞白血病(T-ALL)的预后在青少年和年轻成人(AYA)人群中使用儿科启发方案得到改善。关于儿童方案治疗T-ALL/淋巴母细胞淋巴瘤(LBL) AYA患者的预后的文献有限。方法:采用AYA-15方案治疗35例年龄在14 ~ 55岁的T-ALL/LBL-AYA患者。结果:中位随访5年，总生存率、无病生存率和无事件生存率分别为71%、62%和49.6%。毒性在预期范围内。结论:我们的单中心经验真实世界数据显示，使用儿科启发方案治疗T-ALL/LBL-AYA患者的18-55岁患者具有高生存率和良好耐受性的令人鼓舞的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hematologic Oncology

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.